Introduction
Patients with Type II sialidosis develop progressive mucopolysaccharidosis-like features, including coarse facies, visceromegaly, dysostosis multiplex, and severe mental retardation.
To our knowledge, only one study mentions the assay of chitotriosidase in one sialidosis plasma sample that did not exhibit an increase in enzyme activity [9] . Chitotriosidase is markedly secreted by activated macrophages in various conditions involving inflammatory processes, atherosclerosis and hematological disorders. Increases in this enzyme's activity have also been detected in plasma specimens from some patients with lysosomal storage disorders [9, 10, 17] .
Patients
The main clinical manifestations of P1 and P2 and of previously reported patients with Type II sialidosis are reported in Tables 1 and 2. The infantile and the juvenile  phenotype of Type II sialidosis are presented together in  Table 2. P1 and P2 presented normal beta-galactosidase activity, and, respectively no residual NEU1 activity and 0.31 nmol/ mg/h (vn = 131.5 ± 65.7) NEU1 activity, detected in fibroblasts. P1 exhibits the congenital form of the disease with trombocytopenia and pulmonary interstitial thickening. P2 presented with psychomotor delay, congenital cataract and sensorineural hearing loss in the first year. He went on to develop dysostosis multiplex with regression of psychomotor development, cherry red spot and epilepsy in the early years of childhood. He also presented extremely elevated chitotriosidase levels (12,600 nmol/ml/h vn 25.75 ± 17), about 250 times the normal level.
Both congenital and infantile/juvenile phenotypes, present course facies, psychomotor delay, organomegaly and ocular manifestations. Clinical evidence on Type II patients reveals the distinctive features of congenital sialidosis to be hydrops, ascites, oedema, skin telangiectases and petechie, and hydrocephalus (only one case) [5] . A private and atypical sign of the longer surviving phenotype is microcephaly, found in a 12 year old patient [3] .
Myoclonic seizures are well documented in Type I sialidosis [31] , but it should be noted that 8/17 Type II infantile/juvenile and 3/28 patients with the congenital form exhibited epileptic seizures or myoclonus (Tables 1,  2 ). Renal involvement is present in only a few cases: one belonging to the hydropic form and four to the infantile/ juvenile phenotypes.
Molecular analysis
Molecular analysis identified one known [c.679G [ A (p.G227R)] missense mutation [16] , and the new splicing transition c.807 ? 1G [ A. Both mutations were homozygous.
The splicing defect gives rise to at least one aberrant mRNA transcript containing the genetic sequence of intron 4. This insertion results in the premature UGA stop codon starting at position c.807 ? 13.
In the proximal promoter of P2's chitotriosidase gene (CHIT1) no mutations or SNPs were observed.
Screening of the 24 bp duplication in exon 10 of CHIT1 (leading to a complete but non pathological enzyme defect) showed normal PCR products in both patients.
Discussion
Clinical onset, severity of symptoms and course differ in the congenital and infantile/juvenile subgroups. Ascites and oedema are clearly related to the more severe congenital group of the disease. In longer surviving phenotypes oedema was present in only one infantile patient [26] .
On the other hand some clinical manifestations such as ataxia, anorexia and hearing loss, characteristic of the lateonset Type II subgroups, are likely to become increasingly severe as patients age.
The evaluation of chitotriosidase was useful in the differential diagnosis of the disease in P2. The patient was first hospitalized after epileptic seizures at 1 year of age and was initially suspected of suffering from Gaucher disease due to the high level of plasma chitotriosidase. An increased expression of P2' s CHIT1 was excluded by amplifying and sequencing its promoter region. Thus, plasma chitotriosidase could be a supplementary biochemical marker that might be worth investigating in such patients.
Molecular characterization of P1's NEU1 gene showed the new allelic variant c.807 ? 1G [ A. To our knowledge only one additional splicing defect has been reported [22] .
The known c. 679G [ A (p.G227R) mutation has a relatively high occurrence and our findings support the hypothesis of an European ancestry [3] .
